Rhovac hires investment bank to generate interest in lead candidate
Biotech company Rhovac is on the lookout for a deal or a partnership regarding its lead candidate. International investment managing firm Stifel Nicolaus Europe has been appointed to help with the task.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Danish biotech company Rhovac, spearheaded by Anders Månsson, former executive of Leo Pharma and Ferring Pharmaceuticals, has made it its goal to examine the opportunities of either striking a deal or entering a partnership pertaining to its lead candidate RV001, the company reports in a press relase on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech begins phase III trial with partner MSD
For subscribers
Sanofi pays up to USD 1bn for new multiple myeloma therapy
For subscribers
.jpg&w=384&q=75)
